ArticleMolecular plant pathology2026
Cucumber Mosaic Virus Coat Protein Sequesters Host CDPK7-Like Into Phase-Separated Condensates to Promote Viral Infection.
Article in Molecular plant pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Plant viruses often manipulate host proteins to facilitate infection, but the molecular mechanisms underlying these interactions remain largely unclear. Here, we provide evidence that the cucumber mosaic virus (CMV) coat protein (CP) interacts with the host kinase CDPK7-like in Nicotiana benthamiana. In an overexpression system, this interaction facilitates liquid-liquid phase separation (LLPS), forming condensate-like structures that could influence host immune-related signalling. Strikingly, plants overexpressing the CDPK7-like gene exhibited significantly enhanced resistance against diverse viruses, including potato virus Y and pepper mild mottle virus, yet displayed heightened susceptibility to CMV, suggesting virus-specific hijacking. Notably, a coumarin-based small-molecule LLPS modulator D3 is developed, which selectively targets the critical Thr52 residue within CMV CP to rescue CDPK7-like from LLPS initiation. Stands in contrast to the commercial drug ribavirin (EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.